These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

779 related articles for article (PubMed ID: 11319624)

  • 21. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
    Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
    J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
    Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo.
    Koga S; Hirohata S; Kondo Y; Komata T; Takakura M; Inoue M; Kyo S; Kondo S
    Anticancer Res; 2001; 21(3B):1937-43. PubMed ID: 11497281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice.
    Zhang Y; Ma H; Zhang J; Liu S; Liu Y; Zheng D
    Life Sci; 2008 Jun; 82(23-24):1154-61. PubMed ID: 18485417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of tissue-specific promoter-driven tumor-targeting trans-splicing ribozyme system as a multifunctional cancer gene therapy device in vivo.
    Song MS; Jeong JS; Ban G; Lee JH; Won YS; Cho KS; Kim IH; Lee SW
    Cancer Gene Ther; 2009 Feb; 16(2):113-25. PubMed ID: 18758435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells.
    Braunstein I; Cohen-Barak O; Shachaf C; Ravel Y; Yalon-Hacohen M; Mills GB; Tzukerman M; Skorecki KL
    Cancer Res; 2001 Jul; 61(14):5529-36. PubMed ID: 11454703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
    Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K
    Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model.
    Ji X; Zhang J; Cheng L; Wei F; Li H; Liu X; Chen X; Li C; Wang Y; Huang Q
    Exp Eye Res; 2009 Aug; 89(2):193-9. PubMed ID: 19328781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer-specific killing by the CD suicide gene using the human telomerase reverse transcriptase promoter.
    Liu J; Zou WG; Lang MF; Luo J; Sun LY; Wang XN; Qian QJ; Liu XY
    Int J Oncol; 2002 Sep; 21(3):661-6. PubMed ID: 12168115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcriptional targeting of virus-mediated gene transfer by the human hexokinase II promoter.
    Määttä AM; Korja S; Venhoranta H; Hakkarainen T; Pirinen E; Heikkinen S; Pellinen R; Mäkinen K; Wahlfors J
    Int J Mol Med; 2006 Nov; 18(5):901-8. PubMed ID: 17016620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus.
    Siders WM; Halloran PJ; Fenton RG
    Cancer Gene Ther; 1998; 5(5):281-91. PubMed ID: 9824047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer.
    Kijima T; Osaki T; Nishino K; Kumagai T; Funakoshi T; Goto H; Tachibana I; Tanio Y; Kishimoto T
    Cancer Res; 1999 Oct; 59(19):4906-11. PubMed ID: 10519403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [HSV-TK gene therapy of lung adenocarcinoma xenografts using a hypoxia/radiation dual-sensitive promoter].
    Wang WD; Chen ZT; Li DZ; Duan YZ; Wang ZX; Cao ZH
    Ai Zheng; 2004 Jul; 23(7):788-93. PubMed ID: 15248913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
    Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
    Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach.
    Brand K; Löser P; Arnold W; Bartels T; Strauss M
    Gene Ther; 1998 Oct; 5(10):1363-71. PubMed ID: 9930342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors.
    Adachi Y; Reynolds PN; Yamamoto M; Grizzle WE; Overturf K; Matsubara S; Muramatsu T; Curiel DT
    Cancer Res; 2000 Aug; 60(16):4305-10. PubMed ID: 10969765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer.
    Anderson LM; Swaminathan S; Zackon I; Tajuddin AK; Thimmapaya B; Weitzman SA
    Gene Ther; 1999 May; 6(5):854-64. PubMed ID: 10505111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo.
    Tjuvajev JG; Chen SH; Joshi A; Joshi R; Guo ZS; Balatoni J; Ballon D; Koutcher J; Finn R; Woo SL; Blasberg RG
    Cancer Res; 1999 Oct; 59(20):5186-93. PubMed ID: 10537296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase.
    Bilsland AE; Anderson CJ; Fletcher-Monaghan AJ; McGregor F; Evans TR; Ganly I; Knox RJ; Plumb JA; Keith WN
    Oncogene; 2003 Jan; 22(3):370-80. PubMed ID: 12545158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model.
    Shieh GS; Shiau AL; Yo YT; Lin PR; Chang CC; Tzai TS; Wu CL
    Cancer Res; 2006 Oct; 66(20):9957-66. PubMed ID: 17047058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.